Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FBQAC
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,831
Award facts
- Contract value 100% obligated
- $24,831.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24.8K delivery order to DMS Pharmaceutical Group Inc. on January 23, 2026, for the supply of Entyvio 300 mg vials, a biologic medication used primarily for inflammatory bowel disease treatment. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected through competitive procurement without a set-aside designation. The delivery order carries a firm fixed-price structure with an ultimate completion date of January 26, 2026, and will be fulfilled at the contractor's Park Ridge facility.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support Department of Defense medical supply requirements worldwide. The underlying PPV-G GEN V contract, valued at $499.9M and awarded November 13, 2025, authorizes DLA to issue delivery orders for a comprehensive range of branded and generic pharmaceuticals, biologics, and medical consumables through December 31, 2036. DMS Pharmaceutical Group's established performance across numerous prior delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FBQAC?
SPE2DR26FBQAC was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FBQAC worth?
The government has obligated $24,831 on SPE2DR26FBQAC.
Is contract SPE2DR26FBQAC an order under another contract?
Yes. SPE2DR26FBQAC is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBQAC competed?
The extent of competition for SPE2DR26FBQAC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award